| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Scandinavian Real Heart AB (Publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.018 |
| 52 Week High | SEK 0.11 |
| 52 Week Low | SEK 0.018 |
| Beta | 0.15 |
| 11 Month Change | -32.06% |
| 3 Month Change | -73.11% |
| 1 Year Change | -82.29% |
| 33 Year Change | -97.16% |
| 5 Year Change | n/a |
| Change since IPO | -97.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| 782 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -21.2% | -8.2% | -3.3% |
| 1Y | -82.3% | -4.8% | -1.3% |
Return vs Industry: 782 underperformed the German Medical Equipment industry which returned -4.8% over the past year.
Return vs Market: 782 underperformed the German Market which returned -1.3% over the past year.
Price Volatility
| 782 volatility | |
|---|---|
| 782 Average Weekly Movement | 19.1% |
| Medical Equipment Industry Average Movement | 3.9% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 782's share price has been volatile over the past 3 months.
Volatility Over Time: 782's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 15 | Ina Perkins | realheart.se |
Scandinavian Real Heart AB (Publ) designs and develops an artificial heart. The company engages in developing Realheart TAH to treat advanced stage heart failure. It also develops RealVAD, pulsating left ventricle assist; PulsePump, pulsating flow for heart and lung machines; and Sternal Prosthesis, to fix the sternum after open-chest surgery.
Scandinavian Real Heart AB (Publ) Fundamentals Summary
| 782 fundamental statistics | |
|---|---|
| Market cap | €3.77m |
| Earnings (TTM) | -€6.21m |
| Revenue (TTM) | n/a |
-3,080x
P/S Ratio-0.6x
P/E RatioIs 782 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 782 income statement (TTM) | |
|---|---|
| Revenue | -SEK 14.12k |
| Cost of Revenue | -SEK 15.01m |
| Gross Profit | SEK 15.00m |
| Other Expenses | SEK 86.66m |
| Earnings | -SEK 71.66m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 22, 2024
| Earnings per share (EPS) | -0.37 |
| Gross Margin | -106,209.01% |
| Net Profit Margin | 507,408.77% |
| Debt/Equity Ratio | 10.4% |
How did 782 perform over the long term?
See historical performance and comparison